Category Archives: In the News

Isowater Corporation: “Connecting Nuclear Products to Non-Nuclear Markets”

The Canadian nuclear industry has long been a world leader in research and technology development, from manufacturing novel reactors to globally exporting items such as radioisotopes and deuterium oxide. This progress in technology is causing industries around the world in all sectors to be disrupted, including those related to the use of deuterium oxide. “We’re connecting a traditional nuclear product to non-nuclear markets”, Andrew Stuart, President and CEO of Isowater said.

http://tradecommissioner.gc.ca/canadexport/0002981.aspx?lang=eng

AVP-786: Progress in the Use of Deuterium in Alzheimer’s Treatment

In the continuing clinical trials, Avanir Pharmaceuticals’ drug, AVP-786, is showing the progress being made in the use of deuterium in medical science. Successes like this pharmaceutical will continue to drive forward product development centered around the unique properties of deuterium by the world’s drug developers via their innovative R&D. Furthermore, advancements like this in the multi-billion dollar pharmaceutical industry are significantly improving the quality of patients lives.

www.alzheimersnewstoday.com/avp-786/

Deuterated Drug Purchase Agreement Continues to Validate Deuterium’s Growing Role in the Future of Medicine

The global pharmaceutical industry has been advanced significantly by Vertex [NASDAQ: VRTX] and their potential improvement for the treatment of cystic fibrosis via the use of a novel deuterated drug CTP-656. Vertex’s stock increased a record amount, boosting their market cap by 8 billion USD with shares up 24% after the company shared their data from clinical studies of triple combinations of drug treatments.

For more information on where to buy deuterium oxide, please click the link.

http://investors.vrtx.com/releasedetail.cfm?releaseid=1034371

http://www.marketwatch.com/story/vertex-shares-soar-24-to-all-time-high-on-cystic-fibrosis-drug-studies-2017-07-18

First Deuterated Drug, Austedo (deutrabenazine) by Teva approved by FDA, April 04, 2017

Isowater is pleased to see this precedent setting FDA approval in place for Austedo  by Teva. It has had the developmental name of SD-809. As it is for the treatment of chorea, which is associated with Huntington’s disease, it offers an improved product to reduce the random involuntary twisting movements that accompany people with Huntington’s.  This new deuterated drug will be able to help the quality of daily life for those who currently suffer. Isowater looks forward to a new chapter of drug development and continuing to secure the long-term deuterium supply chain to pharmaceutical firms to create as well as improve pharmaceuticals and importantly the quality of life for others. For more information on how to buy heavy water click here.

 

http://www.tevapharm.com/news/teva_announces_fda_approval_of_austedo_deutetrabenazine_tablets_for_the_treatment_of_chorea_associated_with_huntington_s_disease_04_17.aspx

Deuterium use in Life Science Applications Highlighted in Specialty Chemicals Magazine

Deuterium oxide is being used in key pharmaceutical applications as reported by Dr. Sarah Harding of Specialty Chemicals Magazine in their Pharmaceuticals section of the April 2017 magazine. With a focus on the variety of Life Sciences applications for deuterium oxide that are used to help patients, Isowater plays a key role. Deuteration offers a way to improve even those drugs that already enjoy wide acceptance due to the critical nature of their primary effect, but which reduce patient’s quality of life due to adverse side effects. Isowater’s focus is to ensure that the raw material for deuterated drugs – deuterium – is available and of high quality for the long term needs of the global pharmaceutical supply chain. Find out more on the deuterium atom structure click here.

http://www.specchemonline.com/news/the-lighter-side-of-heavy-water 

The Chemical and Engineering News (C&EN) reports on Deuterated Drugs & Isowater’s Role

 The Chemical and Engineering News (C&EN), a publication of the American Chemical Society is a leading source of technical information for the Life Sciences industry. An article published in early July 2016 provides a summary of the world leading pharmaceutical companies now developing deuterated drugs.   Successful deuterated drugs have up to three ways they can enhance the efficacy of similar non-deuterated drugs. First deuterium reduces the rate at which the body can metabolize the medicine. Secondly due to deuterium’s stability enhancement, longer therapeutic life time may result. Thirdly, the longer the lifetime, the higher the potential to reduce the initial dosage level. Lower doses may lead to reduced side effects. Isowater is supporting the use of deuterium in the pharmaceutical industry through developing strong supply chain products such as multiyear supply arrangements.

http://cen.acs.org/articles/94/i27/Deuterium-switcheroo-breathes-life-old.html

The Economist Magazine Reports on Deuterated Pharmaceuticals

The excitement and growth potential of deuterated pharmaceuticals is going main-stream as reported in the Economist magazine in their Medical Chemistry section (see link below). With the emphasis being “Drugs that live long will prosper”, the article nicely summarizes the outlook for deuterated pharmaceuticals. The ending sentence “…a basic fact: deuterated drugs will soon be widespread, and the result will be fewer pills to swallow” provides a key outlook that Isowater shares. Isowater’s focus is to ensure the raw material for deuterated drugs – deuterium – is available. Currently deuterium oxide (heavy water) is made for nuclear energy applications. Isowater’s focus is to develop supply that is independent of the energy policies of a particular nation and targeted towards the non-nuclear industry applications such as pharmaceuticals, other life sciences, and high tech. Only through independent private sector supply will the growing non-nuclear deuterium dependent industries have a stable base to achieve profitable growth. For more informaion on where to buy heavy water click here.

http://www.economist.com/news/science-and-technology/21663193-simple-change-some-pharmaceuticals-might-boost-their-efficacy-and-make-few

Another Major Investment in Deuterium Technology for Pharmaceuticals

First Auspex Pharmaceuticals announces its IPO priced at $12.00 per share, and now Concert Pharmaceuticals announces its IPO at $14.00 per share.  Auspex and Concert are both working on developing drugs containing deuterium (H2) in place of protium (H1) at key positions.  Both companies have pharma products in the pipeline and both have products that are in mid-phase trials.  Concert has made a number of collaboration agreements with companies to utilize deuterium substitution in pharmaceuticals already on the market.  The principle behind the technology is that deuterium binds more tightly than protium and therefore is less reactive.  Substitution of protium with deuterium in a pharmaceutical is expected to reduce the rate at which the drug is metabolized, thereby allowing a more convenient and safer therapy regimen. The steady pattern of major investment leading to IPOs for both companies supports the confidence that investors have in the ultimate success of this deuterium substitution technology. Contact us as your supplier of deuterium gas for sale.

View the article in Xconomy:

http://www.xconomy.com/boston/2014/02/13/concert-pharma-heads-to-nasdaq-prices-ipo-at-14-per-share/?utm_source=rss&utm_medium=rss&utm_campaign=concert-pharma-heads-to-nasdaq-prices-ipo-at-14-per-share

Major Investment in Technology for Pharmaceuticals

Auspex Pharmaceuticals Inc has raised $35 million which will advance the clinical trials of its deuterium substituted drug SD-809 designed for the treatment of chorea associated with Huntington’s disease.  In addition, the company has appointed an industry veteran, Gerald Proehl, to its Board of Directors says the article in Digital Journal. Auspex has a pipeline of drugs using deuterium substitution in order to lower the rate of breakdown of the active metabolites. While deuterium reduces the breakdown of the active metabolite of the drug, there is no effect on the target or receptor binding of the drug. It is expected that these features will result in a more convenient and safer dosage regimen, separation of pharmacological effects and a number of other benefits. This is another example of investors recognizing the growing importance of deuterium and deuterium oxide in pharmaceutical applications. For more current up to date of our deuterium gas price list click here.

For more information on Auspex

http://www.auspexpharma.com/

To view the article in Digital Journal

http://www.digitaljournal.com/pr/1670835